FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1809-1822 May 3, 2007 Number 18 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Compston, J. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period.

Methods In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes.

Results Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons). Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers. Adverse events, including change in renal function, were similar in the two study groups. However, serious atrial fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001).

Conclusions A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829 [ClinicalTrials.gov] .)

Source Information

From the University of California, San Francisco, San Francisco (D.M.B., T.F.H., D.S.); Université Claude Bernard Lyon 1 and INSERM Research Unit 831, Lyon, France (P.D.D.); University of Sheffield, Sheffield, United Kingdom (R.E.); University of Auckland, Auckland, New Zealand (I.R.R.); Katholieke Universiteit Leuven, Leuven, Belgium (S.B.); University of Pittsburgh, Pittsburgh (J.A.C.); Helen Hayes Hospital, West Haverstraw, NY (F.C.); Semmelweis University Medical School, Budapest, Hungary (P.L.); the Chinese University of Hong Kong, Hong Kong (P.C.L.); Centro Tratamiento Integral Endocrinología Metabolismo Patología Ósea, Buenos Aires (Z.M.); Centro de Osteopatías Médicas, Buenos Aires (C.M.); Novartis Pharmaceuticals, East Hanover, NJ (P.M., H.H., J.C., K.T., T.R.-J., J.K.); Novartis Pharma, Basel, Switzerland (E.F.E.); and San Francisco Coordinating Center, San Francisco (S.R.C.).

Address reprint requests to Dr. Black at the Department of Epidemiology and Biostatistics, University of California, San Francisco, 185 Berry St., Lobby 4, Suite 5700, San Francisco, CA 94107, or at dblack{at}psg.ucsf.edu.

Full Text of this Article

This article has been cited by other articles:

• Hershman, D. L., McMahon, D. J., Crew, K. D., Shao, T., Cremers, S., Brafman, L., Awad, D., Shane, E. (2010). Prevention of Bone Loss by Zoledronic Acid in Premenopausal Women Undergoing Adjuvant Chemotherapy Persist up to One Year following Discontinuing Treatment. J. Clin. Endocrinol. Metab. 95: 559-566 [Abstract] [Full Text]  
• Agis, H., Blei, J., Watzek, G., Gruber, R. (2010). Is Zoledronate Toxic to Human Periodontal Fibroblasts?. JDR 89: 40-45 [Abstract] [Full Text]  
• MILLER, P. D. (2009). Fragility fractures in chronic kidney disease: An opinion-based approach. Cleveland Clinic Journal of Medicine 76: 715-723 [Abstract] [Full Text]  
• Shaker, J. L. (2009). Paget's disease of bone: a review of epidemiology, pathophysiology and management. Therapeutic Advances in Musculoskeletal Diseases 1: 107-125 [Abstract]  
• Rahmani, P., Morin, S. (2009). Prevention of osteoporosis-related fractures among postmenopausal women and older men. CMAJ 181: 815-820 [Full Text]  
• Blake, G. M., Frost, M. L., Fogelman, I. (2009). Quantitative Radionuclide Studies of Bone. JNM 50: 1747-1750 [Full Text]  
• Bobyn, J. D., McKenzie, K., Karabasz, D., Krygier, J. J., Tanzer, M. (2009). Locally Delivered Bisphosphonate for Enhancement of Bone Formation and Implant Fixation. JBJS 91: 23-31 [Full Text]  
• Dell, R. M., Greene, D., Anderson, D., Williams, K. (2009). Osteoporosis Disease Management: What Every Orthopaedic Surgeon Should Know. JBJS 91: 79-86 [Full Text]  
• Ferrari, S. (2009). Continuous broad protection against osteoporotic fractures with strontium ranelate. Rheumatology (Oxford) 48: iv20-iv24 [Abstract] [Full Text]  
• Raj, S. R., Stein, C. M., Saavedra, P. J., Roden, D. M. (2009). Cardiovascular Effects of Noncardiovascular Drugs. Circulation 120: 1123-1132 [Full Text]  
• Dunbar, M. J., Howard, A., Bogoch, E. R., Parvizi, J., Kreder, H. J. (2009). Orthopaedics in 2020: Predictors of Musculoskeletal Need. JBJS 91: 2276-2286 [Full Text]  
• Eastell, R., Black, D. M., Boonen, S., Adami, S., Felsenberg, D., Lippuner, K., Cummings, S. R., Delmas, P. D., Palermo, L., Mesenbrink, P., Cauley, J. A., for the HORIZON Pivotal Fracture Trial, (2009). Effect of Once-Yearly Zoledronic Acid Five Milligrams on Fracture Risk and Change in Femoral Neck Bone Mineral Density. J. Clin. Endocrinol. Metab. 94: 3215-3225 [Abstract] [Full Text]  
• Khosla, S. (2009). Increasing Options for the Treatment of Osteoporosis. NEJM 361: 818-820 [Full Text]  
• Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., Kutilek, S., Adami, S., Zanchetta, J., Libanati, C., Siddhanti, S., Christiansen, C., the FREEDOM Trial, (2009). Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. NEJM 361: 756-765 [Abstract] [Full Text]  
• Nguyen, T. V. (2009). Interpretation of Randomized Controlled Trials of Fracture Prevention. IBMS BoneKEy 6: 279-294 [Abstract] [Full Text]  
• Farley, J. F., Blalock, S. J. (2009). Trends and determinants of prescription medication use for treatment of osteoporosis. Am J Health Syst Pharm 66: 1191-1201 [Abstract] [Full Text]  
• Kennel, K. A., Drake, M. T. (2009). Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management. Mayo Clin Proc. 84: 632-638 [Abstract] [Full Text]  
• Sedghizadeh, P. P. (2009). Author's response. Journal of the American Dental Association 140: 517-518 [Full Text]  
• Fauser, B.C.J.M., Mannaerts, B.M.J.L., Devroey, P., Leader, A., Boime, I., Baird, D.T. (2009). Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update 15: 309-321 [Abstract] [Full Text]  
• O'Sullivan, S., Horne, A., Wattie, D., Porteous, F., Callon, K., Gamble, G., Ebeling, P., Browett, P., Grey, A. (2009). Decreased Bone Turnover Despite Persistent Secondary Hyperparathyroidism during Prolonged Treatment with Imatinib. J. Clin. Endocrinol. Metab. 94: 1131-1136 [Abstract] [Full Text]  
• Bhadada, S. K, Bhansali, A., Das, S., R, A., Rao, S. D (2009). Thrombotic thrombocytopenic purpura following zoledronic acid infusion with a fatal outcome. BMJ Case Reports 2009: bcr0920080923-bcr0920080923 [Abstract] [Full Text]  
• KHAN, A. A., SANDOR, G. K.B., DORE, E., MORRISON, A. D., ALSAHLI, M., AMIN, F., PETERS, E., HANLEY, D. A., CHAUDRY, S. R., LENTLE, B., DEMPSTER, D. W., GLORIEUX, F. H., NEVILLE, A. J., TALWAR, R. M., CLOKIE, C. M., MARDINI, M. A., PAUL, T., KHOSLA, S., JOSSE, R. G., SUTHERLAND, S., LAM, D. K., CARMICHAEL, R. P., BLANAS, N., KENDLER, D., PETAK, S., STE-MARIE, L. G., BROWN, J., EVANS, A.W., RIOS, L., COMPSTON, J. E. (2009). Bisphosphonate Associated Osteonecrosis of the Jaw. The Journal of Rheumatology 36: 478-490 [Abstract] [Full Text]  
• Hegge, K. A., Fornoff, A. S., Gutierres, S. L., Haack, S. L. (2009). New Therapies for Osteoporosis. Journal of Pharmacy Practice 22: 53-64 [Abstract]  
• Grey, A., Bolland, M. J., Wattie, D., Horne, A., Gamble, G., Reid, I. R. (2009). The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. J. Clin. Endocrinol. Metab. 94: 538-544 [Abstract] [Full Text]  
• Poole, K., on behalf of the authors, (2009). Comment on: Hypovitaminosis D among rheumatology outpatients in clinical practice: reply. Rheumatology (Oxford) 48: 204-204 [Full Text]  
• Rietbrock, S., Olson, M., van Staa, T.P. (2009). The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM 102: 35-42 [Abstract] [Full Text]  
• (2008). Annual {blacktriangledown}zoledronic acid for osteoporosis. DTB 46: 93-96 [Abstract] [Full Text]  
• CAREY, J. J., PALOMO, L. (2008). Bisphosphonates and osteonecrosis of the jaw: Innocent association or significant risk?. Cleveland Clinic Journal of Medicine 75: 871-879 [Abstract] [Full Text]  
• Edwards, B. J., Hellstein, J. W., Jacobsen, P. L., Kaltman, S., Mariotti, A., Migliorati, C. A., for the American Dental Association Council on Sci, (2008). Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advisory statement from the American Dental Association Council on Scientific Affairs. Journal of the American Dental Association 139: 1674-1677 [Abstract] [Full Text]  
• Maestri, E., On behalf of Oreste Capelli, Giulio Formoso, Lucia, (2008). Say Dr No to shifting from falls to osteoporosis. BMJ 337: a2684-a2684 [Full Text]  
• Heckbert, S. R., Li, G., Cummings, S. R., Smith, N. L., Psaty, B. M. (2008). Alendronate, Osteoporosis, and Atherosclerosis--Reply. Arch Intern Med 168: 2387-2387 [Full Text]  
• Colon-Emeric, C. S. (2008). Fracture Prevention in Frail Older Adults: Why, When and How. IBMS BoneKEy 5: 426-435 [Abstract] [Full Text]  
• Miki, R. A., Oetgen, M. E., Kirk, J., Insogna, K. L., Lindskog, D. M. (2008). Orthopaedic Management Improves the Rate of Early Osteoporosis Treatment After Hip Fracture. A Randomized Clinical Trial. JBJS 90: 2346-2353 [Abstract] [Full Text]  
• Kearns, A.E., Kallmes, D.F. (2008). Osteoporosis Primer for the Vertebroplasty Practitioner: Expanding the Focus Beyond Needles and Cement. Am. J. Neuroradiol. 29: 1816-1822 [Abstract] [Full Text]  
• Hershman, D. L., McMahon, D. J., Crew, K. D., Cremers, S., Irani, D., Cucchiara, G., Brafman, L., Shane, E. (2008). Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast Cancer. JCO 26: 4739-4745 [Abstract] [Full Text]  
• SINGER, F. R., EYRE, D. R. (2008). Using biochemical markers of bone turnover in clinical practice. Cleveland Clinic Journal of Medicine 75: 739-750 [Abstract] [Full Text]  
• Weiss, H. M., Pfaar, U., Schweitzer, A., Wiegand, H., Skerjanec, A., Schran, H. (2008). Biodistribution and Plasma Protein Binding of Zoledronic Acid. Drug Metab. Dispos. 36: 2043-2049 [Abstract] [Full Text]  
• Berenson, J. R., Yellin, O., Boccia, R. V., Flam, M., Wong, S.-F., Batuman, O., Moezi, M. M., Woytowitz, D., Duvivier, H., Nassir, Y., Swift, R. A. (2008). Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss. Clin. Cancer Res. 14: 6289-6295 [Abstract] [Full Text]  
• Lester, J. E., Dodwell, D., Purohit, O. P., Gutcher, S. A., Ellis, S. P., Thorpe, R., Horsman, J. M., Brown, J. E., Hannon, R. A., Coleman, R. E. (2008). Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer. Clin. Cancer Res. 14: 6336-6342 [Abstract] [Full Text]  
• Qaseem, A., Snow, V., Shekelle, P., Hopkins, R. Jr., Forciea, M. A., Owens, D. K., for the Clinical Efficacy Assessment Subcommittee, (2008). Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians. ANN INTERN MED 149: 404-415 [Abstract] [Full Text]  
• Drake, M. T., Clarke, B. L., Khosla, S. (2008). Bisphosphonates: Mechanism of Action and Role in Clinical Practice. Mayo Clin Proc. 83: 1032-1045 [Abstract] [Full Text]  
• Li, X., McCauley, L. K. (2008). Osteonecrosis of the Jaw: Meeting Report from Skeletal Complications of Malignancy V: October 25-27, 2007 in Philadelphia, Pennsylvania, USA. IBMS BoneKEy 5: 289-293 [Full Text]  
• Woodis, C B. (2008). Once-Yearly Administered Intravenous Zoledronic Acid for Postmenopausal Osteoporosis. The Annals of Pharmacotherapy 42: 1085-1089 [Abstract] [Full Text]  
• Black, D. M., Boonen, S., Delmas, P., Lyles, K. W. (2008). Review of Comparative Effectiveness of Treatments to Prevent Fractures. ANN INTERN MED 148: 885-886 [Full Text]  
• Sander, B., Elliot-Gibson, V., Beaton, D. E., Bogoch, E. R., Maetzel, A. (2008). A Coordinator Program in Post-Fracture Osteoporosis Management Improves Outcomes and Saves Costs. JBJS 90: 1197-1205 [Abstract] [Full Text]  
• Gehrig, L., Lane, J., O'Connor, M. I. (2008). Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons. JBJS 90: 1362-1374 [Full Text]  
• Greenspan, S. L., Brufsky, A., Lembersky, B. C., Bhattacharya, R., Vujevich, K. T., Perera, S., Sereika, S. M., Vogel, V. G. (2008). Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. JCO 26: 2644-2652 [Abstract] [Full Text]  
• Cole, Z., Dennison, E., Cooper, C. (2008). Update on the treatment of post-menopausal osteoporosis. Br Med Bull 86: 129-143 [Abstract] [Full Text]  
• Edwards, B. J., Migliorati, C. A. (2008). Osteoporosis and Its Implications for Dental Patients. Journal of the American Dental Association 139: 545-552 [Abstract] [Full Text]  
• Rozental, T. D., Makhni, E. C., Day, C. S., Bouxsein, M. L. (2008). Improving Evaluation and Treatment for Osteoporosis Following Distal Radial Fractures. A Prospective Randomized Intervention. JBJS 90: 953-961 [Abstract] [Full Text]  
• Brufsky, A., Bundred, N., Coleman, R., Lambert-Falls, R., Mena, R., Hadji, P., Jin, L., Schenk, N., Ericson, S., Perez, E. A., Z-FAST and ZO-FAST Study Groups, (2008). Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole. The Oncologist 13: 503-514 [Abstract] [Full Text]  
• Cauley, J. A., Ensrud, K. E. (2008). Considering Competing Risks . . . Not All Black and White. Arch Intern Med 168: 793-795 [Full Text]  
• Heckbert, S. R., Li, G., Cummings, S. R., Smith, N. L., Psaty, B. M. (2008). Use of Alendronate and Risk of Incident Atrial Fibrillation in Women. Arch Intern Med 168: 826-831 [Abstract] [Full Text]  
• Sorensen, H. T., Christensen, S., Mehnert, F., Pedersen, L., Chapurlat, R. D, Cummings, S. R, Baron, J. A (2008). Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336: 813-816 [Abstract] [Full Text]  
• Majumdar, S. R (2008). Oral bisphosphonates and atrial fibrillation. BMJ 336: 784-785 [Full Text]  
• Compston, J. E. (2008). Zoledronic Acid - Does It Have Anabolic as Well as Anti-Resorptive Effects?. IBMS BoneKEy 5: 103-107 [Full Text]  
• Lloyd, S. A.J., Travis, N. D., Lu, T., Bateman, T. A. (2008). Development of a low-dose anti-resorptive drug regimen reveals synergistic suppression of bone formation when coupled with disuse. J. Appl. Physiol. 104: 729-738 [Abstract] [Full Text]  
• Moore, A. E.B., Blake, G. M., Fogelman, I. (2008). Quantitative Measurements of Bone Remodeling Using 99mTc-Methylene Diphosphonate Bone Scans and Blood Sampling. JNM 49: 375-382 [Abstract] [Full Text]  
• van den Berg, P., Lopez, C. A., Tasneem, Z., Karam, R., Al-Khalidi, H., Steinbuch, M., Colon-Emeric, C. S., Lyles, K. W., Mesenbrink, P., the HORIZON Recurrent Fracture Trial, (2008). Zoledronate, fractures, and mortality after hip fracture.. NEJM 358: 967-968 [Full Text]  
• MacLaughlin, E. J., Raehl, C. L. (2008). ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults. Am J Health Syst Pharm 65: 343-357 [Full Text]  
• MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., Desai, S. B., Zhou, A., Chen, S., Carter, J., Tringale, C., Valentine, D., Johnsen, B., Grossman, J. (2008). Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. ANN INTERN MED 148: 197-213 [Abstract] [Full Text]  
• Granger, C. B, Vogel, V., Cummings, S. R, Held, P., Fiedorek, F., Lawrence, M., Neal, B., Reidies, H., Santarelli, L., Schroyer, R., Stockbridge, N. L, Feng Zhao, (2008). Do we need to adjudicate major clinical events?. Clin Trials 5: 56-60 [Abstract]  
• Reid, I. R. (2008). Pathogenesis of Osteonecrosis of the Jaw. IBMS BoneKEy 5: 69-77 [Abstract] [Full Text]  
• Brufsky, A. M. (2008). Cancer Treatment-Induced Bone Loss: Pathophysiology and Clinical Perspectives. The Oncologist 13: 187-195 [Abstract] [Full Text]  
• Grbic, J. T., Landesberg, R., Lin, S.-Q., Mesenbrink, P., Reid, I. R., Leung, P.-C., Casas, N., Recknor, C. P., Hua, Y., Delmas, P. D., Eriksen, E. F., for the Health Outcomes Reduced Incidence With Zol, (2008). Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial. Journal of the American Dental Association 139: 32-40 [Abstract] [Full Text]  
• Cauley, J. A., Hochberg, M. C., Lui, L.-Y., Palermo, L., Ensrud, K. E., Hillier, T. A., Nevitt, M. C., Cummings, S. R. (2007). Long-term Risk of Incident Vertebral Fractures. JAMA 298: 2761-2767 [Abstract] [Full Text]  
• Vega, D., Maalouf, N. M., Sakhaee, K. (2007). The Role of Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications. J. Clin. Endocrinol. Metab. 92: 4514-4521 [Abstract] [Full Text]  
• Bao, T., Davidson, N. E. (2007). How We Maintain Bone Health in Early-Stage Breast Cancer Patients on Aromatase Inhibitors. J Oncol Pract 3: 323-325 [Full Text]  
• Aubin, J. E., Bouillon, R., Guise, T. A., Reid, I. R. (2007). Meeting Report from the 17th Scientific Meeting of the International Bone and Mineral Society: June 24-29, 2007 in Montreal, Quebec, Canada. IBMS BoneKEy 4: 299-313 [Full Text]  
• Kimmel, D.B. (2007). Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates. JDR 86: 1022-1033 [Abstract] [Full Text]  
• Lyles, K. W., Colon-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., Lavecchia, C., Zhang, J., Mesenbrink, P., Hodgson, P. K., Abrams, K., Orloff, J. J., Horowitz, Z., Eriksen, E. F., Boonen, S., the HORIZON Recurrent Fracture Trial, (2007). Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. NEJM 357: 1799-1809 [Abstract] [Full Text]  
• Johnson, B. E (2007). A once yearly IV infusion of zoledronic acid prevented fractures in postmenopausal women with osteoporosis. Evid. Based Med. 12: 145-145 [Full Text]  
• McDonald, M. M., Schindeler, A., Little, D. G. (2007). Bisphosphonate Treatment and Fracture Repair. IBMS BoneKEy 4: 236-251 [Abstract] [Full Text]  
• de Nijs, R. N.J., Westgeest, A. A.A., Poole, K. E.S., Kaptoge, S., Reeve, J., Karam, R., Camm, J., McClung, M., Najib, M. A., Aziz, I., Chang, J. T., Black, D., Eriksen, E., Sellmeyer, D., Compston, J. (2007). Yearly zoledronic acid in postmenopausal osteoporosis.. NEJM 357: 711-712 [Full Text]  
• (2007). Yearly infusion of zoledronic acid helps prevent fractures in postmenopausal women with osteoporosis. BMJ 335: 36-36 [Abstract] [Full Text]  
• Compston, J. (2007). Treatments for Osteoporosis -- Looking beyond the HORIZON. NEJM 356: 1878-1880 [Full Text]  
• Cummings, S. R., Schwartz, A. V., Black, D. M. (2007). Alendronate and Atrial Fibrillation. NEJM 356: 1895-1896 [Full Text]  
• (2007). Bisphosphonate Therapy . . . Once a Year. JWatch Women's Health 2007: 4-4 [Full Text]  
• (2007). Once-Yearly Treatment for Osteoporosis?. JWatch General 2007: 2-2 [Full Text]